{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:15:43Z","timestamp":1791918943167,"version":"4.3.4"},"reference-count":43,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer's Disease Reports"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer's disease (AD) manifests as an insidiously progressive neurodegenerative pathology, wherein the current therapeutic armamentarium remains constrained to symptomatic management, highlighting an urgent need for innovative therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This meta-analysis systematically conducts an assessment of the safety and efficacy of focused ultrasound (FUS)-mediated reversible blood-brain barrier opening (BBBO) in AD, while further exploring its potential associations with cognitive function and amyloid-\u03b2 (A\u03b2) deposition in patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, CNKI, Cochrane Library, and Web of Science were searched in this study. The study protocol has been registered with PROSPERO (registration number, CRD42024585286). ROBINS-I tool was used to assess the risk of bias, followed by further data analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-seven AD patients from eight distinct clinical studies were systematically incorporated into the meta-analytical framework. The time span was from 2018 to 2023. After FUS-mediated BBBO, the analysis demonstrated significant outcomes of FUS for both safety (OR: 0.88; 95% CI: 0.75\u20130.98, p\u2009&lt;\u20090.01) and efficacy (OR: 0.91; 95% CI: 0.61\u20131.00, p\u2009&lt;\u20090.01). There was no deterioration of cognitive function after surgery, and the observed adverse events were minor and temporary in nature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This meta-analysis underscores the potential of FUS as a non-invasive, safe, and effective method for enhancing BBB permeability in AD patients, offering a promising avenue for targeted drug delivery and disease modification. Future multicenter studies with larger sample sizes and standardized methodologies are warranted to confirm these results and explore the integration of FUS with existing and emerging AD therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/25424823251343789","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T10:37:42Z","timestamp":1747823862000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of focused ultrasound-mediated blood-brain barrier opening in Alzheimer's disease: A systematic review and meta-analysis"],"prefix":"10.1177","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7696-9085","authenticated-orcid":false,"given":"Mengru","family":"Bai","sequence":"first","affiliation":[{"name":"Second School of Clinical Medicine, Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2805-9426","authenticated-orcid":false,"given":"Hanlei","family":"Lyv","sequence":"additional","affiliation":[{"name":"Second School of Clinical Medicine, Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0936-650X","authenticated-orcid":false,"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Second School of Clinical Medicine, Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, the Second Affiliated Hospital of Anhui Medical University, Hefei, China"},{"name":"Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7048-7378","authenticated-orcid":false,"given":"Zhengyi","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, the Second Affiliated Hospital of Anhui Medical University, Hefei, China"},{"name":"Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education Institutes, Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245789"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.854992"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S61288"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14050987"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.02.014"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00139-y"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114539"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0569-x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2023.05.014"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2013.05.008"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa2512"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"e_1_3_3_15_2","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-IV-TR","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.","edition":"4"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_3_17_2","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Br Med J 2016; 355: i4919.","journal-title":"Br Med J"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00455.x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04529-6"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-023-00447-y"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.94206"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-021-00269-8"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac459"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3171\/2022.9.JNS221565"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2002571117"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020250"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/1941738120944254"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2021.0510"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-023-03888-y"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102120"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.85"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.3340\/jkns.2022.0236"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040833"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6965.1351"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.22848"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-023-01107-0"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.14140245"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94188-3"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.089730"},{"key":"e_1_3_3_43_2","unstructured":"Research C for DE and. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. FDA https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs (2019 accessed 1 May 2025)."},{"key":"e_1_3_3_44_2","unstructured":"FDA. CRESTOR (rosuvastatin calcium) tablets [Internet]. 2010. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021366s016lbl.pdf (Accessed 9 February 2015)."}],"container-title":["Journal of Alzheimer's Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823251343789","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25424823251343789","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823251343789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:00:17Z","timestamp":1767679217000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25424823251343789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":43,"alternative-id":["10.1177\/25424823251343789"],"URL":"https:\/\/doi.org\/10.1177\/25424823251343789","relation":{},"ISSN":["2542-4823","2542-4823"],"issn-type":[{"value":"2542-4823","type":"print"},{"value":"2542-4823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"25424823251343789"}}